Alliance Global Partners analyst James Molloy initiated coverage of INmune Bio (INMB) with a Buy rating and $20 price target INmune is developing a pipeline with two main assets: XPro, a tumor necrosis factor inhibitor that is being tested in early Alzheimer’s Disease in a Phase 2 trial, and INKmune, a cell therapy that activates endogenous resting natural killer, or NK, cells in the tumor microenvironment to fight cancer using a patient’s immune system, which is being studied in a Phase 1/2 clinical trial where it is in the Phase 1 dose escalation portion. The firm values the stock on a sum-of-the-parts basis with XPro for AD valued at $14 per share, and INKmune for mCRPC valued at $4 per share plus net cash at $2 per share adding up to its $20 per share price target
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INMB:
- INmune Bio completes enrollment for Phase 2 trial in Early AD
- INmune Bio initiated with an Outperform at Raymond James
- INmune announces initial results from Phase I/II trial of INKmune with mCRPC
- INmune Bio announces results of additional interim analysis of Phase 2 trial
- INmune Bio initiated with an Outperform at Scotiabank on Alzheimer’s potential